Long-term outcomes of intravitreous bevacizumab or tissue plasminogen activator or vitrectomy for macular edema due to branch retinal vein occlusion

Kazuyuki Kumagai,1 Nobuchika Ogino,2 Marie Fukami,1 Mariko Furukawa1 1Kami-iida Daiichi General Hospital, Nagoya, Aichi, Japan; 2Shinjo Ophthalmologic Institute, Miyazaki, Japan Purpose: The purpose of this study was to determine the long-term outcomes of intravitreal bevacizumab (IVB) or intravit...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kumagai K, Ogino N, Fukami M, Furukawa M
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2019
Materias:	branch retinal vein occlusion bevacizumab tissue plasminogen activator vitrectomy macular edema Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/aa88baaabfcc46a7aa88866c94c54a25
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:aa88baaabfcc46a7aa88866c94c54a25
record_format	dspace
spelling	oai:doaj.org-article:aa88baaabfcc46a7aa88866c94c54a252021-12-02T05:38:14ZLong-term outcomes of intravitreous bevacizumab or tissue plasminogen activator or vitrectomy for macular edema due to branch retinal vein occlusion1177-5483https://doaj.org/article/aa88baaabfcc46a7aa88866c94c54a252019-04-01T00:00:00Zhttps://www.dovepress.com/long-term-outcomes-of-intravitreous-bevacizumab-or-tissue-plasminogen--peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Kazuyuki Kumagai,1 Nobuchika Ogino,2 Marie Fukami,1 Mariko Furukawa1 1Kami-iida Daiichi General Hospital, Nagoya, Aichi, Japan; 2Shinjo Ophthalmologic Institute, Miyazaki, Japan Purpose: The purpose of this study was to determine the long-term outcomes of intravitreal bevacizumab (IVB) or intravitreal tissue plasminogen activator (tPA) or vitrectomy for macular edema associated with a branch retinal vein occlusion (BRVO).Methods: This was a retrospective, interventional case series. Forty-one patients received a single 1.25 mg of IVB injection and followed by pro re nata protocol, 71 patients received a single intravitreal tPA, and 116 patients underwent phacovitrectomy with intraocular lens implantation.Results: The baseline characteristics and follow-up periods were not significantly different among the three groups. The mean follow-up period was 55.5 months with a range of 12–160 months. Sixteen patients (39.0%) in the IVB group, 24 patients (33.8%) in the tPA group, and two patients (1.7%) in the vitrectomy group underwent additional surgeries during the follow-up period. The best-corrected visual acuity (BCVA) significantly improved in all groups at 1 year after the initial treatment (all, P<0.0001) and at the final visit (all, P<0.0001). The differences in the BCVA between the three groups were not significant at all times after the initial treatment.Conclusion: The three groups led to similar long-term good visual outcomes. However, additional surgeries were performed in more than 30% of patients in the IVB and tPA groups. Keywords: branch retinal vein occlusion, bevacizumab, tissue plasminogen activator, vitrectomy, macular edemaKumagai KOgino NFukami MFurukawa MDove Medical Pressarticlebranch retinal vein occlusionbevacizumabtissue plasminogen activatorvitrectomymacular edemaOphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 13, Pp 617-626 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	branch retinal vein occlusion bevacizumab tissue plasminogen activator vitrectomy macular edema Ophthalmology RE1-994
spellingShingle	branch retinal vein occlusion bevacizumab tissue plasminogen activator vitrectomy macular edema Ophthalmology RE1-994 Kumagai K Ogino N Fukami M Furukawa M Long-term outcomes of intravitreous bevacizumab or tissue plasminogen activator or vitrectomy for macular edema due to branch retinal vein occlusion
description	Kazuyuki Kumagai,1 Nobuchika Ogino,2 Marie Fukami,1 Mariko Furukawa1 1Kami-iida Daiichi General Hospital, Nagoya, Aichi, Japan; 2Shinjo Ophthalmologic Institute, Miyazaki, Japan Purpose: The purpose of this study was to determine the long-term outcomes of intravitreal bevacizumab (IVB) or intravitreal tissue plasminogen activator (tPA) or vitrectomy for macular edema associated with a branch retinal vein occlusion (BRVO).Methods: This was a retrospective, interventional case series. Forty-one patients received a single 1.25 mg of IVB injection and followed by pro re nata protocol, 71 patients received a single intravitreal tPA, and 116 patients underwent phacovitrectomy with intraocular lens implantation.Results: The baseline characteristics and follow-up periods were not significantly different among the three groups. The mean follow-up period was 55.5 months with a range of 12–160 months. Sixteen patients (39.0%) in the IVB group, 24 patients (33.8%) in the tPA group, and two patients (1.7%) in the vitrectomy group underwent additional surgeries during the follow-up period. The best-corrected visual acuity (BCVA) significantly improved in all groups at 1 year after the initial treatment (all, P<0.0001) and at the final visit (all, P<0.0001). The differences in the BCVA between the three groups were not significant at all times after the initial treatment.Conclusion: The three groups led to similar long-term good visual outcomes. However, additional surgeries were performed in more than 30% of patients in the IVB and tPA groups. Keywords: branch retinal vein occlusion, bevacizumab, tissue plasminogen activator, vitrectomy, macular edema
format	article
author	Kumagai K Ogino N Fukami M Furukawa M
author_facet	Kumagai K Ogino N Fukami M Furukawa M
author_sort	Kumagai K
title	Long-term outcomes of intravitreous bevacizumab or tissue plasminogen activator or vitrectomy for macular edema due to branch retinal vein occlusion
title_short	Long-term outcomes of intravitreous bevacizumab or tissue plasminogen activator or vitrectomy for macular edema due to branch retinal vein occlusion
title_full	Long-term outcomes of intravitreous bevacizumab or tissue plasminogen activator or vitrectomy for macular edema due to branch retinal vein occlusion
title_fullStr	Long-term outcomes of intravitreous bevacizumab or tissue plasminogen activator or vitrectomy for macular edema due to branch retinal vein occlusion
title_full_unstemmed	Long-term outcomes of intravitreous bevacizumab or tissue plasminogen activator or vitrectomy for macular edema due to branch retinal vein occlusion
title_sort	long-term outcomes of intravitreous bevacizumab or tissue plasminogen activator or vitrectomy for macular edema due to branch retinal vein occlusion
publisher	Dove Medical Press
publishDate	2019
url	https://doaj.org/article/aa88baaabfcc46a7aa88866c94c54a25
work_keys_str_mv	AT kumagaik longtermoutcomesofintravitreousbevacizumabortissueplasminogenactivatororvitrectomyformacularedemaduetobranchretinalveinocclusion AT oginon longtermoutcomesofintravitreousbevacizumabortissueplasminogenactivatororvitrectomyformacularedemaduetobranchretinalveinocclusion AT fukamim longtermoutcomesofintravitreousbevacizumabortissueplasminogenactivatororvitrectomyformacularedemaduetobranchretinalveinocclusion AT furukawam longtermoutcomesofintravitreousbevacizumabortissueplasminogenactivatororvitrectomyformacularedemaduetobranchretinalveinocclusion
_version_	1718400314400309248

Long-term outcomes of intravitreous bevacizumab or tissue plasminogen activator or vitrectomy for macular edema due to branch retinal vein occlusion

Ejemplares similares